MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$48,194M
Net Income
$7,054M
Net Profit Margin
14.64%
EPS
$3.46
Unit: Million (M) dollars
Revenue Breakdown
Sales Revenue Gross
Alliance And Other Revenues
Revenue Breakdown
Eliquis
Opdivo
Orencia
Others
Revenue Breakdown
Net Product Sales
Otherrevenues
Alliance Revenues
Revenue Breakdown
US
Non Us
Other Region
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Total revenues
48,194
48,300
45,006
46,159
Cost of products sold
13,936
13,968
10,693
10,137
Selling, general and administrative
7,267
8,414
7,772
7,814
Research and development
9,951
11,159
9,299
9,509
Acquired iprd
3,721
13,373
913
815
Amortization of acquired intangible assets
3,317
8,872
9,047
9,595
Interest expense
-
-
1,166
1,232
Royalty and licensing income (note 4)
-
-
-
1,283
Interest expense
1,891
1,947
-
-
Royalty income - divestitures (note 4)
1,129
1,104
862
832
Royalty and licensing income (note 4)
1,093
736
1,488
-
Investment income
586
478
449
171
Divestiture losses/(gains) (note 4)
-
-15
0
211
Provision for restructuring (note 6)
563
635
365
75
Litigation and other settlements
-434
-84
390
-178
Loss on debt redemption (note 10)
-356
0
0
-266
Contingent consideration (note 9)
351
-
-8
-9
Intangible asset impairment
-
47
-
-
Equity investment (gains)/losses, net (note 9)
280
16
-160
-801
Integration expenses (note 6)
147
284
242
440
Acquisition expense
9
50
-
-
Other
-11
-165
-106
-90
Other (income)/expense, net
-674
-893
1,158
-576
Total expenses
38,866
56,679
36,566
38,446
Earnings/(loss) before income taxes
9,328
-8,379
8,440
7,713
Income tax provision
2,272
554
400
1,368
Net earnings/(loss)
7,055
-8,933
8,040
6,345
Noncontrolling interest
2
15
15
18
Net earnings/(loss) attributable to bms
7,054
-8,948
8,025
6,327
Basic EPS
3.47
-4.41
3.88
2.97
Diluted EPS
3.46
-4.41
3.86
2.95
Basic Average Shares
2,034,000,000
2,027,000,000
2,069,000,000
2,130,000,000
Diluted Average Shares
2,039,000,000
2,027,000,000
2,078,000,000
2,146,000,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
4
Sales Revenue Gross
$88,085M
(5.28%↑ Y/Y)
Net Product Sales
$46,756M
(-0.05%↓ Y/Y)
Alliance And Other
Revenues
$1,438M
(-5.52%↓ Y/Y)
Gross to net
adjustments
-$41,329M
(-12.02%↓ Y/Y)
Total revenues
$48,194M
(-0.22%↓ Y/Y)
Medicaidand
Medicarerebates
-$18,010M
(-8.82%↓ Y/Y)
Chargebacksandcashdiscounts
-$14,067M
(-22.22%↓ Y/Y)
Other Rebates Returns
Discounts And Adjustments
-$9,253M
(-4.77%↓ Y/Y)
Earnings/(loss) before income
taxes
$9,328M
(211.33%↑ Y/Y)
Total expenses
$38,866M
(-31.43%↓ Y/Y)
Net
earnings/(loss)
$7,055M
(178.98%↑ Y/Y)
Income tax provision
$2,272M
(310.11%↑ Y/Y)
Cost of products sold
$13,936M
(-0.23%↓ Y/Y)
Research and development
$9,951M
(-10.83%↓ Y/Y)
Selling, general and
administrative
$7,267M
(-13.63%↓ Y/Y)
Acquired iprd
$3,721M
(-72.18%↓ Y/Y)
Amortization of acquired
intangible assets
$3,317M
(-62.61%↓ Y/Y)
Other
(income)/expense, net
-$674M
(24.52%↑ Y/Y)
Royalty income -
divestitures (note 4)
$1,129M
(2.26%↑ Y/Y)
Royalty and licensing
income (note 4)
$1,093M
(48.51%↑ Y/Y)
Investment income
$586M
(22.59%↑ Y/Y)
Equity investment
(gains)/losses, net (note 9)
$280M
(1650.00%↑ Y/Y)
Net
earnings/(loss) attributable to...
$7,054M
(178.83%↑ Y/Y)
Noncontrolling interest
$2M
(-86.67%↓ Y/Y)
Interest expense
$1,891M
(-2.88%↓ Y/Y)
Provision for
restructuring (note 6)
$563M
(-11.34%↓ Y/Y)
Litigation and other
settlements
-$434M
(-416.67%↓ Y/Y)
Loss on debt
redemption (note 10)
-$356M
Contingent consideration
(note 9)
$351M
Integration expenses (note
6)
$147M
(-48.24%↓ Y/Y)
Other
-$11M
(93.33%↑ Y/Y)
Acquisition expense
$9M
(-82.00%↓ Y/Y)
Buy us a coffee
BRISTOL MYERS SQUIBB CO (BMYMP)
BRISTOL MYERS SQUIBB CO (BMYMP)